Your browser doesn't support javascript.
loading
A clinical impact study of dermatologists' use of diagnostic gene expression profile testing to guide patient management.
Witkowski, Alexander; Jarell, Abel D; Ahmed, Kelli L; Siegel, Jennifer J; Russell, Brooke H; Rogers, Jason H; Goldberg, Matthew S; Fernandes, Neil F; Ludzik, Joanna; Farberg, Aaron S.
Afiliación
  • Witkowski A; Department of Dermatology, Oregon Health & Science University, Portland, OR, USA.
  • Jarell AD; Granite State Dermatology, PC, Portsmouth, NH, USA.
  • Ahmed KL; Castle Biosciences, Inc., Friendswood, TX, USA.
  • Siegel JJ; Castle Biosciences, Inc., Friendswood, TX, USA.
  • Russell BH; Castle Biosciences, Inc., Friendswood, TX, USA.
  • Rogers JH; Castle Biosciences, Inc., Friendswood, TX, USA.
  • Goldberg MS; Castle Biosciences, Inc., Friendswood, TX, USA.
  • Fernandes NF; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Ludzik J; Skin & Cancer Center of Arizona, Chandler, AZ, USA.
  • Farberg AS; Department of Dermatology, Oregon Health & Science University, Portland, OR, USA.
Melanoma Manag ; 11(1): MMT68, 2024.
Article en En | MEDLINE | ID: mdl-38812731
ABSTRACT

Aim:

Cutaneous melanocytic neoplasms with diagnostic and/or clinical ambiguity pose patient management challenges.

Methods:

Six randomized case scenarios with diagnostic/clinical uncertainty were described with/without a benign or malignant diagnostic gene expression profile (GEP) result.

Results:

Clinical impact was assessed by reporting the mean increase/decrease of management changes normalized to baseline (n = 32 dermatologists). Benign GEP results prompted clinicians to decrease surgical margins (84.2%). Malignant GEP results escalated surgical excision recommendations (100%). A majority (72.2%) reduced and nearly all (98.9%) increased follow-up frequency for benign or malignant GEP results, respectively. There was an overall increase in management plan confidence with GEP results.

Conclusion:

Diagnostic GEP tests help guide clinical decision-making in a variety of diagnostically ambiguous or clinicopathologically discordant scenarios.
Dermatologists' use of diagnostic gene expression profiles for personalized patient care. When your doctor takes a piece of a mole, that mole is looked at under the microscope by a pathologist. The pathologist is responsible for figuring out if the mole is dangerous or not. Dangerous moles are removed with surgery to make sure all the dangerous tissue is gone. Moles without a health threat are left alone. Sometimes figuring out how dangerous a mole is is difficult. The pathologist may not provide the doctor with enough information for them to know how to treat your mole. There is a test that can provide information on whether your mole is unsafe. This test is called diagnostic gene expression profiling or GEP. In this study, GEP is used to help doctors figure out how to treat a mole and how often the patient should be seen in the office for skin checks. With GEP, important changes in patient treatment were identified. These include the need for an additional surgery, how much healthy tissue should be removed during surgery and how often the patient should be seen in the office. For suspicious moles where the pathology report is unclear, GEP can provide information that leads to more appropriate and personalized patient care.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Melanoma Manag Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Melanoma Manag Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos